Bionomics Limited (BNOX)
NASDAQ: BNOX · Real-Time Price · USD
0.295
+0.017 (5.97%)
At close: Nov 22, 2024, 4:00 PM
0.292
-0.002 (-0.78%)
After-hours: Nov 22, 2024, 7:43 PM EST
Bionomics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
24
Market Cap
5.75M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 35.36M |
| SunLink Health Systems | 31.81M |
| Biomerica | 5.51M |
| Predictive Oncology | 1.48M |
| Mainz Biomed | 917.20K |
BNOX News
- 14 days ago - Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement - GlobeNewsWire
- 18 days ago - Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program - GlobeNewsWire
- 4 weeks ago - Bionomics to Present at the ThinkEquity Conference - GlobeNewsWire
- 5 weeks ago - Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - GlobeNewsWire
- 7 weeks ago - Bionomics Limited announces intention to re-domicile to the United States - GlobeNewsWire
- 2 months ago - Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - GlobeNewsWire
- 4 months ago - Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 - GlobeNewsWire